World Malaria Day: Drug Development Overview

ArticlesBSV Insights
Written By Michael Wielander

On World Malaria Day on April 25th, it is worth asking: what does innovation in malaria treatment look like today?

For decades, malaria treatment has relied on a relatively narrow set of mechanisms. Artemisinin-based combination therapies (ACTs) remain the standard of care more than 25 years after their introduction. However, signs of artemisinin partial resistance (defined as delayed parasite clearance following treatment) have increased the focus on reducing reliance on this therapeutic backbone.

One of the most promising late-stage candidates for this is ganaplacide + lumefantrine (GanLum), a non-artemisinin combination currently in development by a Novartis-led consortium. Ganaplacide is a novel compound from the imidazolopiperazine class*, identified through large-scale screening, while lumefantrine provides a long-standing longer-acting partner.

In a Phase III trial across 12 African countries (n>1,600; adults and children), the combination showed high cure rates comparable to standard ACTs. Results published at the end of last year showed 99.2% of those treated with the new combination were cured, compared with 96.7% of patients who received the ACT Coartem. Ganaplacide is also being evaluated as a monotherapy in Phase II. While efficacy is comparable, the relevance of GanLum lies in its potential to provide a non-artemisinin alternative, particularly in the context of emerging resistance. This positions GanLum as a potential alternative to current regimens rather than a variation within them. If approved, the key question will not only be efficacy, but also how to deploy such therapies to preserve long-term effectiveness.

*Imidazolopiperazines (IZPs) are a novel class of antimalarials with multistage activity across the Plasmodium lifecycle, including asexual blood stages, liver stages, and gametocytes, likely acting through disruption of mitochondrial function, inhibition of sodium homeostasis, and interference with protein trafficking, while retaining activity against artemisinin-resistant parasites and offering potential for both treatment and transmission reduction.

At the same time, the current pipeline remains largely focused on targeting parasite biology. Among 18 other antimalarial drugs currently in clinical development (Phases 2 and 1) and 25 preclinical candidates, the majority continue to target the pathogen directly.

Host-targeted approaches remain limited. Two notable examples currently in the pipeline include CD147-targeting antibodies such as meplazumab (Phase I/II; Jiangsu Pacific Meinuoke) and IBX-13 (preclinical; Ibex Biosciences), which aim to block parasite invasion into red blood cells by interfering with host–parasite interactions.

A more fundamental shift may come from recent findings by Marini and colleagues. Their work suggests that reduced cyclin D3 expression in erythroid progenitors can make red blood cells less permissive to parasite growth. This points to a different intervention model: modifying host biology rather than directly targeting the parasite to inhibit malaria infection. It also raises the possibility that pathways already explored in oncology, such as cyclin D–related pathways, could be relevant in malaria, although safety and selectivity remain key challenges. While still early, this kind of cross-therapeutic thinking could open a fundamentally different innovation path.

Other developments continue in parallel, including new parasite targets, simplified dosing strategies, following the first approved malaria treatment specifically developed for newborns and young infants.

Malaria innovation is expanding beyond optimizing existing therapies to diversifying mechanisms and exploring new points of intervention.

Sources and links:

 
Michael Wielander
Next

Bioscience Valuation at the BioEntrepreneur Bootcamp 2026